🇨🇭June 18, 2026·10h agoIndustry

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

Publisher

Roche Newsroom

Switzerland

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Roche Newsroom
Region: Switzerland
Scope: Industry
Published: June 18, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on roche.com

Leave the platform to read the original full article on the publisher site.

Source: Roche Newsroom

Scope: Industry

Open original article

Related coverage

More related coverage

Bristol-Myers Squibb News/4h ago

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Merck & Co. (MSD) News/4h ago

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Ipsen RSS/6h ago

Advancing Care in Renal Cell Carcinoma: Earlier Treatment, Better Outcomes, and Stronger Support for Patients

Natco Pharma/15h ago

natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26